Qiagen

{{short description|German biotechnology company}} {{Use dmy dates|date=May 2023}} {{Infobox company | name = QIAGEN N.V. | logo = 130px | type = Public (''Naamloze vennootschap'') | traded_as = {{Unbulleted list|{{NYSE|QGEN}}|{{FWB|QIA}}|Russell 1000 component|DAX component}} | ISIN = {{ISIN|sl=n|pl=y|NL0015001WM6}} | founders = {{Unbulleted list|Metin Colpan| Karsten Henco| Jürgen Schumacher}} | area_served = | key_people = {{Unbulleted list|Thierry Bernard (CEO)| Lawrence A. Rosen (chairman of supervisory board)}} | industry = Biotechnology | products = | revenue = {{decrease}} {{US$|1.97 billion|link=yes}} (2023) | operating_income = {{decrease}} {{US$|410 million}} (2023) | net_income = {{decrease}} {{US$|341 million}} (2023) | assets = {{decrease}} {{US$|6.12 billion}} (2023) | equity = {{increase}} {{US$|3.81 billion}} (2023) | num_employees = 5,967 (2023) | divisions = | subsid = | foundation = {{start date and age|1984|11|29}} | location = {{Unbulleted list|Venlo, Netherlands (corporate) |Hilden, Germany (operational)}} | owner =  | website = {{URL|qiagen.com}} | footnotes = <ref>{{Cite web |url=https://www.sec.gov/ix?doc=/Archives/edgar/data/1015820/000101582024000022/qgen-20231231.htm |title=2023 Annual Report (Form 20-F) |date=11 March 2024 |publisher=US Securities and Exchange Commission}}</ref><ref>{{cite web |url=https://corporate.qiagen.com/about-us/Who-we-are/management/supervisory-board/ |url-status=dead |archive-url=https://web.archive.org/web/20170711030116/http://corporate.qiagen.com/about-us/Who-we-are/management/supervisory-board |archive-date=2017-07-11 |title=Supervisory Board}}</ref> }}

'''QIAGEN N.V.''' is a German-founded multinational provider of sample and assay technologies for molecular diagnostics, applied testing, academic research, and pharmaceutical research. The company operates in more than 35 offices in over 25 countries. QIAGEN N.V., the global corporate headquarter of the QIAGEN group, is located in Venlo, The Netherlands. The main operative headquarters are located in Hilden, Germany.<ref>{{Cite web |title=Our global presence {{!}} QIAGEN |url=http://www.qiagen.com/eg/about-us/our-global-presence |access-date=2024-02-22 |website=www.qiagen.com |language=de}}</ref> European, American, Chinese, and Asian-Pacific regional headquarters are located respectively in Hilden, Germany; Germantown, Maryland, United States; Shanghai, China; and Singapore.<ref>{{cite web |date=2024-02-20 |title=Company Presentation |url=https://s28.q4cdn.com/125951340/files/doc_downloads/resources/QIAGEN_Company-presentation.pdf |access-date=2024-02-20 |website=corporate.qiagen.com}}</ref> QIAGEN's shares are listed at the NYSE (using ticker QGEN) and at the Frankfurt Stock Exchange in the Prime Standard (using ticker QIA). Thierry Bernard is the company's Chief Executive Officer (CEO).

== History ==

In 1984, QIAGEN was established on November 29 by a team of scientists at the Heinrich Heine University Düsseldorf, Germany. Two years later, QIAGEN launched its first product. A kit for the purification of plasmids—small ring-shaped DNA molecules in bacterial cells.<ref>{{Cite web |title=Historical Development {{!}} QIAGEN |url=http://www.qiagen.com/eg/about-us/our-history |access-date=2024-02-22 |website=www.qiagen.com |language=de}}</ref> 1996 saw the initial public offering of QIAGEN on the American technology-oriented Nasdaq stock exchange, becoming the first German company to do so.<ref>{{cite book | title= A Vision for Venture Capital: Realizing the Promise of Global Venture Capital and Private Equity (Winthrop Group) | isbn=978-1584657996 | author=Peter A. Brooke, Daniel Penrice |date= Nov 10, 2009}}</ref> 1997 saw the initial public offering on the Frankfurt Stock Exchange in Germany.<ref>{{Cite web |title=Historical Development {{!}} QIAGEN |url=http://www.qiagen.com/eg/about-us/our-history |access-date=2024-02-22 |website=www.qiagen.com |language=de}}</ref>

===Acquisitions and Business Development Timeline===

In 2004, QIAGEN acquired key assets of Molecular Staging, Inc.<ref>{{cite web |last1=Sheridan |first1=Cormac |title=Qiagen Pays $28.5M Cash For Molecular Staging Technology |url=https://www.bioworld.com/articles/375896-qiagen-pays-28-5m-cash-for-molecular-staging-technology?v=preview |access-date=1 March 2024 |website=bioworld.com}}</ref> Two years later, QIAGEN established its Asia regional headquarters in Shanghai. In 2007 sales were US$649.8 million with more than 2,600 employees. QIAGEN acquired Digene for US$1.6 billion, furthering QIAGEN in molecular diagnostics by revenue and diagnostics for disease prevention.<ref>{{cite web |last1=Flaherty |first1=Michael |last2=James |first2=Steve |title=Netherlands' Qiagen buying Digene for $1.6 bln |url=https://www.reuters.com/article/idUSN03411508/ |access-date=1 March 2024 |website=reuters.com |publisher=Reuters}}</ref>

In 2009, QIAGEN began building its Personalized Healthcare business through the acquisition of DxS Ltd, in a deal valued at US$95 million<ref>{{cite web |last1=Burger |first1=Ludwig |title=Qiagen raises capital, buys DxS |url=https://www.reuters.com/article/uk-qiagen/qiagen-raises-capital-buys-dxs-idUKTRE58L6I620090922/ |access-date=1 March 2024 |website=reuters.com}}</ref> and it acquired SABiosciences Corp. in a deal valued at US$90 million.<ref>{{cite web |title=Qiagen Acquires SABiosciences for $90M |url=https://www.genomeweb.com/dxpgx/qiagen-acquires-sabiosciences-90m |access-date=1 March 2024 |website=genomeweb.com}}</ref> During this year it released a clinically verified diagnostic test for the detection of H1N1, more commonly known as Swine Flu.<ref>{{cite web |title=Qiagen Releases Influenza A/H1N1 Detection Kit for Research Purposes |url=https://www.genengnews.com/news/qiagen-releases-influenza-a-h1n1-detection-kit-for-research-purposes/ |access-date=1 March 2024 |website=genengnews.com}}</ref> During 2009 QIAGEN had over US$1 billion in revenue and over 3,500 employees.

In 2010, QIAGEN acquired ESE GmbH for point of need testing devices for the application of molecular diagnostic tests without laboratory infrastructure.<ref>{{cite web |title=QIAGEN Acquires ESE GmbH |url=https://www.bionity.com/en/news/111706/qiagen-acquires-ese-gmbh.html |access-date=1 March 2024 |website=bionity.com}}</ref>

In 2011, QIAGEN acquired Ipsogen S.A. for US$101 million, adding to the company's product and IP portfolio in the blood cancer space.<ref>{{cite web |title=Qiagen übernimmt Mehrheit von Ipsogen |url=https://www.aerztezeitung.de/Wirtschaft/Qiagen-uebernimmt-Mehrheit-von-Ipsogen-281344.html |access-date=1 March 2024 |website=aerztezeitung.de |publisher=Springer Medizin Verlag GmbH}}</ref> QIAGEN also acquired Cellestis Limited for US$374 million, giving the company access to QuantiFERON technology for disease detection and prevention.<ref>{{cite web |title=Qiagen Completes Cellestis Acquisition |url=https://www.genomeweb.com/pcr/qiagen-completes-cellestis-acquisition |access-date=1 March 2024 |website=genomeweb.com}}</ref> The company added two new offices in the Asia Pacific region in New Delhi, India and Taipei, Taiwan. The company announced a comprehensive restructuring program to focus on high-growth areas such as personalized medicine and business in emerging markets. The program includes workforce reduction and internal restructuring affecting approximately 10% of the company's 3,900 positions.<ref>{{cite web |title=Qiagen to Cut 8-10 Percent of Workforce in Restructuring |url=https://www.genomeweb.com/archive/qiagen-cut-8-10-percent-workforce-restructuring |access-date=1 March 2024 |website=genomeweb.com}}</ref>

In 2013, QIAGEN acquired Ingenuity Systems.<ref>{{cite web |last1=Burger |first1=Ludwig |title=Qiagen buys genetic data processor Ingenuity for $105 million |url=https://www.reuters.com/article/idUSBRE93S0VW/ |access-date=1 March 2024 |website=reuters.com}}</ref> QIAGEN also acquired CLC bio, which offers bioinformatics analysis software.<ref>{{cite web |title=QIAGEN Acquires CLC Bio |url=https://www.technologynetworks.com/informatics/news/qiagen-acquires-clc-bio-206525 |access-date=1 March 2024 |website=technologynetworks.com}}</ref>

In 2015, QIAGEN acquired AdnaGen's circulating tumor cell enrichment technology.<ref>{{cite web |title=QIAGEN Expands Leadership in Liquid Biopsies |url=https://www.technologynetworks.com/diagnostics/news/qiagen-expands-leadership-in-liquid-biopsies-206568 |access-date=1 March 2024 |website=technologynetworks.com}}</ref> QIAGEN also acquired Enzymatic enzyme solutions.<ref>{{cite web |last1=Mullin |first1=Emily |title=Qiagen acquires Enzymatics, gains NGS partner ArcherDX |url=https://www.fiercebiotech.com/medical-devices/qiagen-acquires-enzymatics-gains-ngs-partner-archerdx |access-date=1 March 2024 |website=fiercebiotech.com |publisher=Questex LLC}}</ref> In March 2015, Qiagen divested its Marseille unit through a management buyout that led to the creation of HalioDx.<ref>{{cite web |last1=Wasserman |first1=Emily |title=French cancer Dx company born after management buyout at Qiagen unit |url=https://www.fiercebiotech.com/medical-devices/french-cancer-dx-company-born-after-management-buyout-at-qiagen-unit |access-date=1 March 2024 |website=fiercebiotech.com |publisher=Questex LLC}}</ref> In late 2015 the GeneReader NGS System was launched,<ref>{{cite web |last1=Karow |first1=Julia |title=Qiagen Launches GeneReader NGS System at AMP; Presents Performance Evaluation by Broad |url=https://www.genomeweb.com/molecular-diagnostics/qiagen-launches-genereader-ngs-system-amp-presents-performance-evaluation |access-date=1 March 2024 |website=genomeweb.com}}</ref> and the acquisition of Mo Bio Laboratories was completed.<ref>{{cite web |title=Qiagen Projects Q4, 2015 Shortfalls; Reports Acquisition of Mo Bio Labs |url=https://www.genomeweb.com/business-news/qiagen-projects-q4-2015-shortfalls-reports-acquisition-mo-bio-labs |access-date=1 March 2024 |website=genomeweb.com}}</ref>

In 2016, QIAGEN acquired the Danish molecular diagnostics company Exiqon.<ref>{{cite web |title=Qiagen Completes Exiqon Tender Offer |url=https://www.genomeweb.com/business-news/qiagen-completes-exiqon-tender-offer |access-date=1 March 2024 |website=genomeweb.com}}</ref>

In 2017, QIAGEN acquired OmicSoft Corporation, a leading provider of highly curated public datasets.<ref>{{cite web |last1=Rodríguez Fernández |first1=Clara |title=Qiagen acquires Multi Omics Company to boost its Bioinformatics services |url=https://www.labiotech.eu/trends-news/qiagen-omicsoft-multi-omics/ |access-date=1 March 2024 |website=labiotech.eu |publisher=Labiotech UG}}</ref>

In 2018, QIAGEN transferred its U.S. listing to the New York Stock Exchange.<ref>{{cite web |title=Qiagen To Transfer U.S. Listing Of Global Shares To Nyse |url=https://www.reuters.com/article/brief-qiagen-to-transfer-us-listing-of-g/brief-qiagen-to-transfer-u-s-listing-of-global-shares-to-nyse-idUSFWN1O80YK/ |access-date=1 March 2024 |website=reuters.com}}</ref> In April 2018, QIAGEN acquired the Spanish firm STAT-Dx and launched the QIAstat-Dx molecular diagnostics platform.<ref>{{cite web |last1=Dale |first1=Alex |title=New Diagnostic Tests On the Way as Qiagen Snaps Up a Spanish Biotech |url=https://www.labiotech.eu/trends-news/diagnostic-tests-qiagen-stat-dx/ |access-date=1 March 2024 |website=labiotech.eu |publisher=Labiotech UG}}</ref>

In 2019, QIAGEN announced the acquisition of Formulatrix assets to develop a digital PCR platform.<ref>{{cite web |title=FORMULATRIX® digital PCR technology to be acquired by QIAGEN |url=https://www.the-scientist.com/formulatrix-digital-pcr-technology-to-be-acquired-by-qiagen-65312 |access-date=1 March 2024 |website=the-scientist.com}}</ref> An additional acquisition of N-of-One, a privately held U.S. molecular decision support company and pioneer in clinical interpretation services for complex genomic data, allowed it to expand its Qiagen Clinical Insights (QCI) bioinformatics offerings.<ref>{{cite web |title=QIAGEN To Acquire N-of-One, Inc. - Quick Facts |url=https://markets.businessinsider.com/news/stocks/qiagen-to-acquire-n-of-one-inc-quick-facts-1027846329 |access-date=1 March 2024 |website=markets.businessinsider.com |publisher=Insider Inc. |archive-date=1 March 2024 |archive-url=https://web.archive.org/web/20240301114238/https://markets.businessinsider.com/news/stocks/qiagen-to-acquire-n-of-one-inc-quick-facts-1027846329 |url-status=dead }}</ref> In October 2019 QIAGEN entered into an agreement with Illumina granting QIAGEN non-exclusive rights to develop and globally commercialize *in vitro* diagnostic kits to be used together with Illumina's diagnostic instruments.<ref>{{cite web |last1=Anderson |first1=Chris |title=Illumina and Qiagen Enter 15-Year Diagnostics Partnership |url=https://www.insideprecisionmedicine.com/news-and-features/illumina-and-qiagen-enter-15-year-diagnostics-partnership/ |access-date=1 March 2024 |website=insideprecisionmedicine.com |publisher=Mary Ann Liebert Inc., publishers}}</ref>

In September 2020 QIAGEN announced the acquisition of Michigan-based NeuMoDx Inc. giving it two fully integrated systems for automated PCR.<ref>{{cite web |last1=Taylor |first1=Nick Paul |title=Qiagen completes takeover of PCR automation player NeuMoDx for $248M |url=https://www.medtechdive.com/news/qiagen-completes-248m-takeover-of-pcr-automation-player-neumodx/585481/ |access-date=1 March 2024 |website=medtechdive.com |publisher=Industry Dive}}</ref>

In May 2022, QIAGEN acquired the majority stake in BLIRT S.A., adding new R&D and manufacturing capabilities for customized and standardized recombinant enzymes, as well as molecular biology reagents.<ref>{{cite web |title=Qiagen Acquires Majority Stake in Enzyme Provider Blirt |url=https://www.genomeweb.com/business-news/qiagen-acquires-majority-stake-enzyme-provider-blirt |access-date=1 March 2024 |website=genomeweb.com}}</ref>

In January 2023, the business announced its intention to acquire Verogen for $150 million. This deal included acquiring GEDmatch, a genetic genealogy service.<ref>{{cite web |title=Qiagen acquires DNA-biometrics firm Verogen in $150 mln deal |url=https://www.reuters.com/markets/deals/qiagen-acquires-dna-biometrics-firm-verogen-150-mln-deal-2023-01-09/ |access-date=1 March 2024 |website=reuters.com}}</ref>

{{hidden begin|border=1px #aaa solid|title=Qiagen Acquisitions|ta1=center}} {{Tree list}} *'''Qiagen''' **Molecular Staging, Inc. (Acq 2004) **Digene (Acq 2007) **Corbett Life Science (Acq 2008) **DxS Ltd (Acq 2009) **SABiosciences Corp. (Acq 2009) **ESE GmbH (Acq 2010) **Ipsogen S.A. (Acq 2011) **Cellestis Limited (Acq 2011) **Ingenuity Systems (Acq 2013) **CLC bio (Acq 2013) **Exiqon (Acq 2016) **STAT-Dx (Acq 2018) **Formulatrix (Acq 2019) **OmicSoft (Acq 2017) **N-of-One (Acq 2019) **Molecular Staging, Inc. (Acq 2020) **NeuMoDx Molecular Inc (Acq 2020) **Verogen (Acq 2023) {{Tree list/end}} {{hidden end}}

=== 2020 Thermo Fisher Acquisition Target ===

On March 3, 2020, Thermo Fisher Scientific announced plans for the acquisition of QIAGEN at €39 per share in cash, which valued the transaction at $11.5 billion at the time.<ref>{{cite news |last1=Terry |first1=Mark |title=Thermo Fisher Expands Diagnostics Capabilities with $11.5 Billion Takeover of Qiagen |url=https://www.biospace.com/article/thermo-fisher-to-acquire-qiagen-for-11-5-billion/ |access-date=22 August 2020 |publisher=BioSpace.com |date=3 March 2020 |ref=BioSpace}}</ref> The day after an open letter by hedge fund Davidson Kempner Capital Management, one of QIAGEN's largest shareholders, to reject the bid as undervalued, Thermo Fisher raised their tender by 10% to €43 per share, an advance of $1B in value.<ref>{{cite news |last1=Keown |first1=Alex |title=Thermo Fisher Ups QIAGEN Bid by $1 Billion |url=https://www.biospace.com/article/thermo-fisher-ups-qiagen-bid-by-1-billion/ |access-date=22 August 2020 |publisher=BioSpace.com |date=17 July 2020 |ref=BioSpace2}}</ref>

The acquisition offer was terminated on August 13, 2020, having only reached the threshold of 47% shareholder approval, below the minimum 66.6% required as per the agreement. Because of the lapsed offer, QIAGEN was required to reimburse $95 million to Thermo Fisher in expenses.<ref>{{cite news |last1=Slabodkin |first1=Greg |last2=Rachal |first2=Maria |last3=Paul Taylor |first3=Nick |title=Thermo Fisher-Qiagen deal falls apart after failing to secure shareholder support |url=https://www.medtechdive.com/news/thermo-fisher-nixes-planned-acquisition-of-qiagen-fails-to-secure-sharehol/583446/ |access-date=22 August 2020 |publisher=MedTechDive.com |date=13 August 2020 |ref=MedTechDive}}</ref>

Resulting from the failed takeover bid, QIAGEN announced it would buy the outstanding 80.1% of shares in NeuMoDx Molecular Inc., which it did not already own, for about $234 million.<ref>{{Cite news|url=https://uk.reuters.com/article/us-qiagen-m-a-thermo-fisher/thermo-fishers-qiagen-bid-fails-after-target-gets-covid-testing-boost-idUKKCN2591P3|archive-url=https://web.archive.org/web/20200814132457/https://uk.reuters.com/article/us-qiagen-m-a-thermo-fisher/thermo-fishers-qiagen-bid-fails-after-target-gets-covid-testing-boost-idUKKCN2591P3|url-status=dead|archive-date=2020-08-14|title = Thermo Fisher's Qiagen bid fails after target gets COVID testing boost|newspaper = Reuters|date = 13 August 2020}}</ref>

== References == <references />

Category:Research support companies Category:Companies based in North Rhine-Westphalia Category:Biotechnology companies of Germany Category:German companies established in 1984 Category:Biotechnology companies established in 1984 Category:Companies listed on the New York Stock Exchange Category:Companies listed on the Frankfurt Stock Exchange Category:Companies formerly listed on the Nasdaq Category:German brands Category:Companies in the DAX index Category:Companies in the TecDAX Category:Companies formerly in the MDAX Category:companies based in Limburg (Netherlands) Category:Venlo Category:Cross-listed companies Category:1996 initial public offerings